PlexBio Co., Ltd. (TPEX:6572)

Market Cap	1.05B
Revenue (ttm)	128.06M
Net Income (ttm)	-61.63M
Shares Out	103.65M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,149
Average Volume	35,415
Open	10.10
Previous Close	10.00
Day's Range	9.92 - 10.45
52-Week Range	8.57 - 13.65
Beta	0.09
RSI	47.17
Earnings Date	Aug 14, 2025

About ROIC

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was f...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6572

Financial Performance

In 2024, PlexBio's revenue was 128.06 million, a decrease of -23.40% compared to the previous year's 167.18 million. Losses were -61.63 million, 5.30% more than in 2023.